| API Products | EDMF | CEP | USA DMF | CANADA DMF | WHO | JAPAN | BRAZIL | CHINA CDE |
|---|---|---|---|---|---|---|---|---|
| Abiraterone Acetate | √ | √ | √ | √ | √ | √ | ||
| Apalutamide |
√ |
√ |
Q4 2024 | |||||
| Bempedoic acid | √ | √ | √ | |||||
| Betamethasone Valerate | √ |
|
|
√ | ||||
| Brivaracetam | √ | √ | √ | √ | ||||
| Budesonide | Q4 2024 | Q4 2024 | ||||||
| Elagolix | √ | √ | ||||||
| Enzalutamide | √ | √ | √ | |||||
| Eplerenone | √ | √ | √ | √ | √ | |||
| Dydrogesterone | √ | √ | √ | √ | ||||
| Semaglutide | √ | |||||||
| Fluticasone Propionate | √ | √ | √ | √ | ||||
| Fluticasone Furoate | √ | √ | √ | √ | ||||
| Mometasone Furoate | √ | √ | √ |
|
||||
| Nusinersen(ASO,Oligonucleotides) | Q4 2024 | Q4 2024 | Q4 2024 | |||||
| Pregabalin | √ | √ | √ | √ | ||||
| Relugolix(NEC-1 date 2024.12.18) |
|
√ | ||||||
|
TDF (Tenofovir Disoproxil Fumarate) |
√ | √ | √ | √ | ||||
|
TAF (Tenofovir Alafenamide Hemifumarate) |
√ | √ | √ | |||||
|
TMF (Tenofovir Alafenamide Monofumarate) |
√ | √ | √ | |||||
| Vibegron |
|
√ | ||||||
| Rimegepant | Q2 2025 | Q1 2025 |
※ Disclaimer:
Products protected by valid patents in this list are for laboratory analytical/research purposes only and are not offered for sale in countries or area wherethe sale of such products constitutes a patent infringement.Any liability is at buyer's risk.
Follow Aoruite WeChat official account
